A wave of diagnostic tests—some here, some coming—can identify cancer and Alzheimer’s at earlier stages and predict flare-ups ...

Pfizer is paying $1.25 billion to join the PD-(L1)xVEGF bispecific race. | Pfizer is paying $1.25 billion to join the ...

Hilary Evans-Newton is the Chief Executive of Alzheimer’s Research UK. Hilary joined Alzheimer’s Research UK in 2013 and has overseen significant growth in income in recent years, which has ...

The FDA has cleared the first blood test to diagnose Alzheimer's which works by measuring the amount of pTau 217 and ...

The first Alzheimer's blood test cleared by the Food And Drug Administration is poised to change the way doctors diagnose and ...

The blood test measures two subtypes of tau and amyloid proteins, which can indicate the presence of amyloid plaque in the ...

The blood test is used to detect abnormal protein deposits in the brain that are associated with Alzheimer's. The test is for people 55 and older who are already showing signs of the disease, ...

The FDA greenlit marketing for the first blood test to help diagnose Alzheimer’s disease. Experts believe this will increase ...

The test may make it easier to identify whether people with memory and thinking problems have Alzheimer’s or not.

The first in vitro diagnostic device that uses blood samples to detect Alzheimer disease has been granted marketing clearance by the US Food and Drug Administration.

Experts say the test could dramatically improve access to earlier, more accurate diagnoses, particularly for older Americans ...

The Lumipulse blood test identifies the presence of amyloid plaques, a hallmark of Alzheimer’s disease that impairs normal ...